Glaukos Corporation $GKOS Shares Sold by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC lessened its stake in shares of Glaukos Corporation (NYSE:GKOS) by 8.6% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,340 shares of the medical instruments supplier’s stock after selling 689 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Glaukos were worth $758,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the company. Bessemer Group Inc. raised its position in shares of Glaukos by 133.9% during the 1st quarter. Bessemer Group Inc. now owns 276 shares of the medical instruments supplier’s stock worth $27,000 after purchasing an additional 158 shares during the last quarter. First Horizon Advisors Inc. increased its stake in shares of Glaukos by 72.9% in the first quarter. First Horizon Advisors Inc. now owns 377 shares of the medical instruments supplier’s stock worth $37,000 after buying an additional 159 shares during the last quarter. Principal Financial Group Inc. boosted its holdings in Glaukos by 21.8% in the first quarter. Principal Financial Group Inc. now owns 327,036 shares of the medical instruments supplier’s stock worth $32,187,000 after purchasing an additional 58,502 shares during the period. Capital Management Associates Inc acquired a new stake in shares of Glaukos in the 1st quarter worth about $217,000. Finally, Valeo Financial Advisors LLC raised its stake in shares of Glaukos by 1.5% during the first quarter. Valeo Financial Advisors LLC now owns 7,817 shares of the medical instruments supplier’s stock valued at $769,000 after purchasing an additional 117 shares in the last quarter. Hedge funds and other institutional investors own 99.04% of the company’s stock.

Glaukos Stock Up 1.2%

Shares of NYSE:GKOS opened at $75.55 on Tuesday. Glaukos Corporation has a 1 year low of $73.73 and a 1 year high of $163.71. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.51 and a quick ratio of 4.69. The business’s 50-day moving average is $86.12 and its 200-day moving average is $91.76. The company has a market capitalization of $4.33 billion, a price-to-earnings ratio of -45.79 and a beta of 0.76.

Glaukos (NYSE:GKOS) last issued its earnings results on Wednesday, July 30th. The medical instruments supplier reported ($0.24) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.02. The business had revenue of $124.12 million during the quarter, compared to the consensus estimate of $115.49 million. Glaukos had a negative return on equity of 8.59% and a negative net margin of 21.43%.The firm’s revenue for the quarter was up 29.7% on a year-over-year basis. During the same period in the previous year, the company posted ($0.52) earnings per share. Glaukos has set its FY 2025 guidance at EPS. Equities research analysts predict that Glaukos Corporation will post -1.08 earnings per share for the current year.

Wall Street Analyst Weigh In

GKOS has been the topic of a number of research reports. BTIG Research reiterated a “buy” rating and issued a $104.00 target price on shares of Glaukos in a report on Monday, October 20th. Stifel Nicolaus set a $115.00 price objective on shares of Glaukos in a research note on Monday. Truist Financial decreased their price target on Glaukos from $126.00 to $120.00 and set a “buy” rating on the stock in a research report on Monday, September 22nd. Wells Fargo & Company increased their target price on Glaukos from $86.00 to $92.00 and gave the company an “equal weight” rating in a research note on Thursday, July 31st. Finally, UBS Group boosted their price objective on Glaukos from $125.00 to $134.00 and gave the company a “buy” rating in a research report on Thursday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, Glaukos has an average rating of “Moderate Buy” and an average price target of $116.92.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.